EUVIMEDEUVIMED entdecken
Crossref

An Endocellulase‐Triggered NO Targeted‐Release Enzyme‐Prodrug Therapy System and Its Application in Ischemia Injury

Bo He, Yating Zhang, Huaping Liu, Manuel Tang, Ke Yang, Silian Cheng, Jie Shen, Yongzhen Wei, Weiliang Deng, Qiang Zhao iD, Guang-Yu Yang iD

Advanced Healthcare Materials · 2024

DOI: 10.1002/adhm.202401599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Bo He und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic and Developmental Sciences, School of Life Science…. Hauptthemen laut MEDLINE: Prodrugs, Nitric Oxide, Ischemia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Instrumental Analysis Center, Shanghai Jiao Tong University, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nitric oxide (NO) is a crucial gaseous signaling molecules in regulating cardiovascular, immune, and nervous systems. Controlled and targeted NO delivery is imperative for treating cancer, inflammation, and cardiovascular diseases. Despite various enzyme‐prodrug therapy (EPT) systems facilitating controlled NO release, their clinical utility is hindered by nonspecific NO release and undesired metabolic consequence. In this study, a novel EPT system is presented utilizing a cellobioside‐diazeniumdiolate (Cel2‐NO) prodrug, activated by an endocellulase (Cel5A‐h38) derived from the rumen uncultured bacterium of Hu sheep. This system demonstrates nearly complete orthogonality, wherein Cel2‐NO prodrug maintains excellent stability under endogenous enzymes. Importantly, Cel5A‐h38 efficiently processes the prodrug without recognizing endogenous glycosides. The targeted drug release capability of the system is vividly illustrated through an in vivo near‐infrared imaging assay. The precise NO release by this EPT system exhibits significant therapeutic potential in a mouse hindlimb ischemia model, showcasing reductions in ischemic damage, ambulatory impairment, and modulation of inflammatory responses. Concurrently, the system enhances tissue repair and promotes function recovery efficacy. The novel EPT system holds broad applicability for the controlled and targeted delivery of essential drug molecules, providing a potent tool for treating cardiovascular diseases, tumors, and inflammation‐related disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsNitric OxideIschemiaAnimalsMiceSheepHindlimbMaleHumansAzo Compounds

Stichwörter der Autor:innen

endocellulaseenzyme‐prodrug therapynitric oxidetargeted delivery

Substanzen

ProdrugsNitric OxidediazeniumdiolateAzo Compounds

Autor:innen und Institutionen

  • State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic and Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240,…
  • State Key Laboratory of Medicinal Chemical Biology, Haihe Laboratory of Sustainable Chemical Transformations, Key Laboratory of Bioactive Materials (Ministry of Education), Frontiers Science Center for Cell Responses, C…
  • Tianjin Key Laboratory of Molecular Drug Research, College of Pharmacy, Nankai University, Tianjin, 300353, China.
  • Institute of Key Raw Material, Shanghai Academy of Experimental Medicine, Shanghai, 201401, China.

ORCID-Profile: Qiang Zhao, Guang-Yu Yang

Förderung

  • Instrumental Analysis Center
  • Shanghai Jiao Tong University
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Shanghai Pilot Program for Basic Research

Zitieren

APA

He, B., Zhang, Y., Liu, H., Tang, M., Yang, K., Cheng, S., Shen, J., Wei, Y., Deng, W., Zhao, Q., & Yang, G. Y. (2024). An Endocellulase‐Triggered NO Targeted‐Release Enzyme‐Prodrug Therapy System and Its Application in Ischemia Injury. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202401599

Vancouver

He B, Zhang Y, Liu H, Tang M, Yang K, Cheng S, et al. An Endocellulase‐Triggered NO Targeted‐Release Enzyme‐Prodrug Therapy System and Its Application in Ischemia Injury. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202401599

BibTeX
@article{He2024,
  author = {He, Bo and Zhang, Yating and Liu, Huaping and Tang, Manuel and Yang, Ke and Cheng, Silian and Shen, Jie and Wei, Yongzhen and Deng, Weiliang and Zhao, Qiang and Yang, Guang-Yu},
  title = {An Endocellulase‐Triggered NO Targeted‐Release Enzyme‐Prodrug Therapy System and Its Application in Ischemia Injury},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  doi = {10.1002/adhm.202401599}
}
Kostenlos starten →